Premium
Cancer Immunotherapy: Mesoporous Silica as a Versatile Platform for Cancer Immunotherapy (Adv. Mater. 34/2019)
Author(s) -
Nguyen Thanh Loc,
Choi Youngjin,
Kim Jaeyun
Publication year - 2019
Publication title -
advanced materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.707
H-Index - 527
eISSN - 1521-4095
pISSN - 0935-9648
DOI - 10.1002/adma.201970243
Subject(s) - mesoporous silica , cancer immunotherapy , immunotherapy , materials science , scaffold , cancer , mesoporous material , nanotechnology , cancer cell , phagocytosis , cancer research , microbiology and biotechnology , biomedical engineering , biology , medicine , catalysis , biochemistry
The two different pathways to activate host immature dendritic cells (DCs) into mature antigen‐presenting DCs for cancer immunotherapy using mesoporous silica nanoparticles (MSNs) and mesoporous silica microrods (MSRs) are discussed by Jaeyun Kim and co‐workers in article number 1803953. MSNs deliver immunomodulators into immature DCs by phagocytosis to active them, while the macroporous scaffold composed of randomly stacked MSRs recruits immature DCs and activates them in artificial microenvironments generated by the scaffold itself.